A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
← catalyst calendarNCT07448155 · readout in 61 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
126estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-19 | actual | When the study began enrolling |
| Primary completion | 2026-10-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: INCA033989
- Drug: Bioavailability enhancer
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusion
measured Up to 12 weeks
Pharmacokinetics Parameter: AUClast of INCA33989 following a single SC administration compared with a single IV infusion
measured Up to 12 weeks
Pharmacokinetics Parameter: AUC0∞ of INCA33989 following a single SC administration compared with a single IV infusion
measured Up to 12 weeks
Number of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 12 weeks
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed